Forest Laboratories says that a new clinical trial of its experimental Alzheimer's drug showed sufficient clinical activity to warrant continued studies. About a year ago researchers at Forest reported that neramexane had failed a late-stage trial. The most recent study included 198 patients in 47 sites. Forest had hoped to include 400 subjects. In one set of comparisons, patients taking neramexane showed significant improvement after 12 weeks of treatment but not after 24 weeks.
- read this report from TheStreet.com for more